{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:31:02Z","timestamp":1773891062547,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024JH2\/102600067"],"award-info":[{"award-number":["2024JH2\/102600067"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024JH2\/101900006"],"award-info":[{"award-number":["2024JH2\/101900006"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172822"],"award-info":[{"award-number":["82172822"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017952","name":"Health Commission of Liaoning Province","doi-asserted-by":"publisher","award":["YXMJ-JC-10"],"award-info":[{"award-number":["YXMJ-JC-10"]}],"id":[{"id":"10.13039\/100017952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105058","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:05:48Z","timestamp":1764345948000},"page":"105058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nectins: Orchestrating tumor progression and immune evasion"],"prefix":"10.1016","volume":"217","author":[{"given":"Rongtao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-4496","authenticated-orcid":false,"given":"Shanshan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"DE VISSER","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib2","first-page":"32","article-title":"Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development","volume":"1","author":"GAO","year":"2025","journal-title":"Med Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/jb\/mvg198","article-title":"Roles of the intercellular adhesion molecule nectin in intracellular signaling","volume":"134","author":"SHIMIZU","year":"2003","journal-title":"J. Biochem."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105058_bib4","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1099\/jgv.0.000804","article-title":"Comparison of the antiviral potential among soluble forms of herpes simplex virus type-2 glycoprotein D receptors, herpes virus entry mediator A, nectin-1 and nectin-2, in transgenic mice","volume":"98","author":"FUJIMOTO","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The Anti-Nectin 4: a Promising Tumor Cells Target. A Systematic Review","volume":"21","author":"BOULEFTOUR","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105058_bib6","article-title":"Therapeutic prospects of nectin-4 in cancer: applications and value","volume":"14","author":"LI","year":"2024","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051261","article-title":"Spatial Heterogeneity of Intratumoral Microbiota: a new frontier in cancer immunotherapy resistance","volume":"13","author":"TAN","year":"2025","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"CHANG","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib9","article-title":"The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis [J]","volume":"8","author":"HARRISON","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105058_bib10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nsmb.2366","article-title":"Nectin ectodomain structures reveal a canonical adhesive interface","volume":"19","author":"HARRISON","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00018-014-1763-4","article-title":"Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity","volume":"72","author":"SAMANTA","year":"2015","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pro.2628","article-title":"Crystal structure of afadin PDZ domain-nectin-3 complex shows the structural plasticity of the ligand-binding site","volume":"24","author":"FUJIWARA","year":"2015","journal-title":"Protein Sci."},{"key":"10.1016\/j.critrevonc.2025.105058_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.ctdb.2014.11.019","article-title":"Nectins and nectin-like molecules in development and disease","volume":"112","author":"MANDAI","year":"2015","journal-title":"Curr. Top. Dev. Biol."},{"issue":"37","key":"10.1016\/j.critrevonc.2025.105058_bib14","doi-asserted-by":"crossref","first-page":"14836","DOI":"10.1073\/pnas.1212912109","article-title":"Structure of Nectin-2 reveals determinants of homophilic and heterophilic interactions that control cell-cell adhesion","volume":"109","author":"SAMANTA","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105058_bib15","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/prot.25596","article-title":"Molecular and structural bases of interaction between extracellular domains of nectin-2 and N-cadherin","volume":"86","author":"DURAIVELAN","year":"2018","journal-title":"Proteins"},{"key":"10.1016\/j.critrevonc.2025.105058_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2020.11.052","article-title":"An evolutionarily conserved charged residue dictates the specificity of heterophilic interactions among nectins","volume":"534","author":"DURAIVELAN","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1349-7006.2003.tb01499.x","article-title":"Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization","volume":"94","author":"TAKAI","year":"2003","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib18","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1074\/jbc.C200707200","article-title":"Direct binding of cell polarity protein PAR-3 to cell-cell adhesion molecule nectin at neuroepithelial cells of developing mouse","volume":"278","author":"TAKEKUNI","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.critrevonc.2025.105058_bib19","first-page":"19631","article-title":"Interaction of integrin alpha(v)beta3 with nectin","volume":"281","author":"SAKAMOTO","year":"2006","journal-title":"Implic. Cross Talk. Cell Matrix Cell Cell Junctions J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1083\/jcb.145.3.539","article-title":"Nectin\/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein","volume":"145","author":"TAKAHASHI","year":"1999","journal-title":"J. Cell Biol."},{"issue":"52","key":"10.1016\/j.critrevonc.2025.105058_bib21","doi-asserted-by":"crossref","first-page":"50749","DOI":"10.1074\/jbc.M209846200","article-title":"Trans-interactions of nectins induce formation of filopodia and Lamellipodia through the respective activation of Cdc42 and Rac small G proteins","volume":"277","author":"KAWAKATSU","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.critrevonc.2025.105058_bib22","doi-asserted-by":"crossref","first-page":"28167","DOI":"10.1074\/jbc.M303586200","article-title":"Tage4\/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration","volume":"278","author":"IKEDA","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"42","key":"10.1016\/j.critrevonc.2025.105058_bib23","doi-asserted-by":"crossref","first-page":"36667","DOI":"10.1074\/jbc.M110.200535","article-title":"Interaction of nectin-like molecule 2 with integrin alpha6beta4 and inhibition of disassembly of integrin alpha6beta4 from hemidesmosomes","volume":"286","author":"MIZUTANI","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"Pt 16","key":"10.1016\/j.critrevonc.2025.105058_bib24","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1242\/jcs.099572","article-title":"The role of nectins in different types of cell-cell adhesion","volume":"125","author":"RIKITAKE","year":"2012","journal-title":"J. Cell Sci."},{"issue":"Pt 12","key":"10.1016\/j.critrevonc.2025.105058_bib25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1242\/jcs.024620","article-title":"Involvement of the nectin-afadin complex in PDGF-induced cell survival","volume":"121","author":"KANZAKI","year":"2008","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1242\/jcs.159400","article-title":"Connections matter--how viruses use cell\u2013cell adhesion components","volume":"128","author":"MATEO","year":"2015","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11912-023-01360-1","article-title":"Nectin-4: a Tumor Cell Target and Status of Inhibitor Development","volume":"25","author":"BOULEFTOUR","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"5-6","key":"10.1016\/j.critrevonc.2025.105058_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/15216540600719622","article-title":"Nectins and nectin-like molecules: roles in cell adhesion, polarization, movement, and proliferation","volume":"58","author":"OGITA","year":"2006","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib29","first-page":"4731","article-title":"Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion","volume":"15","author":"LI","year":"2018","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105058_bib30","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/cas.13992","article-title":"Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?","volume":"110","author":"BEKES","year":"2019","journal-title":"Cancer Sci."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105058_bib31","doi-asserted-by":"crossref","first-page":"10930","DOI":"10.1158\/0008-5472.CAN-05-1890","article-title":"CD155\/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics","volume":"65","author":"SLOAN","year":"2005","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105058_bib32","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"TAKANO","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105058_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00358","article-title":"A role for PVRL4-driven cell-cell interactions in tumorigenesis","volume":"2","author":"PAVLOVA","year":"2013","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55460-9","article-title":"Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis","volume":"9","author":"KEDASHIRO","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib35","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41598-021-86437-2","article-title":"Nectin-4 and p95-ErbB2 cooperatively regulate Hippo signaling-dependent SOX2 gene expression, enhancing anchorage-independent T47D cell proliferation","volume":"11","author":"KEDASHIRO","year":"2021","journal-title":"Sci. Rep."},{"issue":"9-10","key":"10.1016\/j.critrevonc.2025.105058_bib36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s10495-018-1473-8","article-title":"CD155 downregulation synergizes with adriamycin to induce breast cancer cell apoptosis","volume":"23","author":"GAO","year":"2018","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00595-015-1126-2","article-title":"Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis","volume":"45","author":"IZUMI","year":"2015","journal-title":"Surg. Today"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1759-7714.2011.00104.x","article-title":"Expression of nectin 3: Novel prognostic marker of lung adenocarcinoma","volume":"3","author":"MANIWA","year":"2012","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105058_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopha.2018.11.020","article-title":"Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells","volume":"110","author":"XU","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105058_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CMAR.S505549","article-title":"Promotion mechanisms of stromal cell-mediated lung cancer development within tumor microenvironment","volume":"17","author":"WU","year":"2025","journal-title":"Cancer Manag Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ncb3478","article-title":"A mechanically active heterotypic E-cadherin\/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion","volume":"19","author":"LABERNADIE","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biocel.2018.07.011","article-title":"The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-\u03b24","volume":"102","author":"SIDDHARTH","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105058_bib43","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET\/CT Imaging of Advanced Urothelial Carcinoma","volume":"29","author":"DUAN","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105058_bib44","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer","volume":"10","author":"VIKAS","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12967-022-03563-9","article-title":"Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients","volume":"20","author":"SEITZ","year":"2022","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib46","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1210\/jc.2007-0040","article-title":"Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy","volume":"92","author":"HUANG","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105058_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000499569","article-title":"Nectin-1 expression in colorectal cancer: is there a group of patients with high risk for early disease recurrence?","volume":"96","author":"TAMPAKIS","year":"2019","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00595-017-1618-3","article-title":"Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma","volume":"48","author":"YAMADA","year":"2018","journal-title":"Surg. Today"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib49","first-page":"59","article-title":"Expression of entry receptor nectin-1 of herpes simplex virus 1 and\/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues","volume":"50","author":"GUZMAN","year":"2006","journal-title":"Acta Virol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00470","article-title":"Nectin-4 Positivity in Genitourinary Malignancies: a systematic review","author":"CRUPI","year":"2024","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11864-022-00940-w","article-title":"Nectin-4: a novel therapeutic target for skin cancers","volume":"23","author":"HASHIMOTO","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"FABRE-LAFAY","year":"2007","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105058_bib53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/glia.20823","article-title":"Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site","volume":"57","author":"GAO","year":"2009","journal-title":"Glia"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105058_bib54","doi-asserted-by":"crossref","first-page":"11845","DOI":"10.1074\/jbc.M112.405993","article-title":"Reduction of the ST6 \u03b2-galactosamide \u03b1-2,6-sialyltransferase 1 (ST6GAL1)-catalyzed sialylation of nectin-like molecule 2\/cell adhesion molecule 1 and enhancement of ErbB2\/ErbB3 signaling by microRNA-199a","volume":"288","author":"MINAMI","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105058_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/jclinpath-2016-204028","article-title":"Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma","volume":"70","author":"KAWANISHI","year":"2017","journal-title":"J. Clin. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib56","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance [J]","volume":"29","author":"KL\u00fcMPER","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.23080","article-title":"The CD155\/poliovirus receptor enhances the proliferation of ras-mutated cells","volume":"122","author":"KONO","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.21021","article-title":"Tightly regulated induction of the adhesion molecule necl-5\/CD155 during rat liver regeneration and acute liver injury","volume":"43","author":"ERICKSON","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1365-2133.2003.05225.x","article-title":"The expression of nectin-1alpha in normal human skin and various skin tumours [J]","volume":"148","author":"MATSUSHIMA","year":"2003","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"MERRILL","year":"2004","journal-title":"Neuro Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105058_bib61","article-title":"Vaccine and immune cell therapy in non-small cell lung cancer","volume":"10","author":"OLIVERES","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib62","first-page":"537","article-title":"Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape","volume":"30","author":"CATROS","year":"2014","journal-title":"Med. Sci."},{"key":"10.1016\/j.critrevonc.2025.105058_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745939","article-title":"Tumor-experienced human nk cells express high levels of PD-L1 and inhibit CD8(+) T cell proliferation","volume":"12","author":"SIERRA","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib64","doi-asserted-by":"crossref","DOI":"10.34133\/research.0723","article-title":"Natural killer cell immune checkpoints and their therapeutic targeting in cancer treatment","volume":"8","author":"LIN","year":"2025","journal-title":"Research"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105058_bib65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.semcancer.2006.07.002","article-title":"The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance","volume":"16","author":"FUCHS","year":"2006","journal-title":"Semin Cancer Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105058_bib66","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"ZHANG","year":"2018","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105058_bib67","first-page":"852","article-title":"CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity","volume":"39","author":"ZHANG","year":"2023","journal-title":"Xi Bao Yu Fen. Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.critrevonc.2025.105058_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","article-title":"Tumor intrinsic and extrinsic immune functions of CD155","volume":"65","author":"O'DONNELL","year":"2020","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.molimm.2016.12.003","article-title":"Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2","volume":"81","author":"SAMANTA","year":"2017","journal-title":"Mol. Immunol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105058_bib70","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"EL-SHERBINY","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105058_bib71","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.str.2024.03.012","article-title":"Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2","volume":"32","author":"HU","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.critrevonc.2025.105058_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-10-34","article-title":"Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients","volume":"10","author":"XU","year":"2009","journal-title":"BMC Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20191290","article-title":"Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells","volume":"217","author":"OKUMURA","year":"2020","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib74","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","article-title":"Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells","volume":"183","author":"CARLSTEN","year":"2009","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib75","first-page":"2960","article-title":"Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors","volume":"17","author":"XU","year":"2019","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"YU","year":"2009","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/intimm\/dxab085","article-title":"DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses","volume":"33","author":"SHIBUYA","year":"2021","journal-title":"Int Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib78","first-page":"62","article-title":"Breaking Boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"LI","year":"2025","journal-title":"Med Res."},{"issue":"11-12","key":"10.1016\/j.critrevonc.2025.105058_bib79","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00335-018-9770-7","article-title":"Interaction of PVR\/PVRL2 with TIGIT\/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer","volume":"29","author":"STAMM","year":"2018","journal-title":"Mamm. Genome"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105058_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060877","article-title":"DNAM-1 and the TIGIT\/PVRIG\/TACTILE Axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy","volume":"11","author":"SANCHEZ-CORREA","year":"2019","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12121306","article-title":"Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: will this break through the limitations of the legacy approach?","volume":"12","author":"CUI","year":"2024","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib82","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jid.2021.01.027","article-title":"Regulatory T CElls Prevent Neutrophilic Infiltration of Skin during Contact Hypersensitivity Reactions by Strengthening the Endothelial Barrier","volume":"141","author":"RING","year":"2021","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"NIKANJAM","year":"2025","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105058_bib84","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"POWLES","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105058_bib85","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"ZHANG","year":"2025","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105058_bib86","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2767-9764.CRC-24-0176","article-title":"ETx-22, a novel nectin-4-directed antibody-drug conjugate, demonstrates safety and potent antitumor activity in low-nectin-4-expressing tumors","volume":"4","author":"LOPEZ","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib87","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"BT8009; A Nectin-4 Targeting bicycle toxin conjugate for treatment of solid tumors","volume":"21","author":"RIGBY","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105058_bib88","article-title":"Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials","volume":"16","author":"ZHANG","year":"2025","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105058_bib89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.actbio.2022.12.023","article-title":"Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer","volume":"158","author":"WU","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2025.105058_bib90","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2023.04.004","article-title":"Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses","volume":"357","author":"XU","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.critrevonc.2025.105058_bib91","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.actbio.2024.02.003","article-title":"A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy","volume":"177","author":"WANG","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2025.105058_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120604","article-title":"Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy","volume":"269","author":"QIU","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2025.105058_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5194780","article-title":"Physical properties of nanoparticles that result in improved cancer targeting","volume":"2020","author":"ZEIN","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241249073","article-title":"Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer","volume":"16","author":"DOMB","year":"2024","journal-title":"Ther. Adv. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib95","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody-Drug Conjugates","volume":"15","author":"LOGANZO","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib96","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"LI","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib97","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.7150\/thno.51299","article-title":"A general Fc engineering platform for the next generation of antibody therapeutics","volume":"11","author":"CHEN","year":"2021","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105058_bib98","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bulcan.2023.07.009","article-title":"Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day","volume":"110","author":"RANCHON","year":"2023","journal-title":"Bull. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","article-title":"Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy","volume":"54","author":"JIN","year":"2021","journal-title":"BMB Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105058_bib100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11912-022-01281-5","article-title":"Clinical development of anti-tigit antibodies for immunotherapy of cancer","volume":"24","author":"FLOROU","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"HARJUNP\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105058_bib102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"RUDIN","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"NIU","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105058_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005829","article-title":"AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors","volume":"11","author":"FRENTZAS","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105058_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.914406","article-title":"Emergence of the CD226 Axis in Cancer Immunotherapy","volume":"13","author":"CONNER","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105058_bib106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2023.07.058","article-title":"Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy","volume":"677","author":"GANGULI","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","article-title":"Targeting TIGIT for cancer immunotherapy: recent advances and future directions","volume":"12","author":"ZHANG","year":"2024","journal-title":"Biomark. Res."},{"issue":"8004","key":"10.1016\/j.critrevonc.2025.105058_bib108","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"GUAN","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib109","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"KLEIN","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105058_bib110","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.2147\/CMAR.S330637","article-title":"A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy","volume":"13","author":"LIANG","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105058_bib111","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s10637-025-01529-4","article-title":"Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignancies","volume":"43","author":"MA","year":"2025","journal-title":"Invest New Drugs"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105058_bib112","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.7150\/jca.29937","article-title":"Targeting immunotherapy for bladder cancer by using anti-CD3 \u00d7 CD155 bispecific antibody","volume":"10","author":"MA","year":"2019","journal-title":"J. Cancer"},{"issue":"3-4","key":"10.1016\/j.critrevonc.2025.105058_bib113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","article-title":"Immune regulation and control of regulatory T cells by OX40 and 4-1BB","volume":"19","author":"SO","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105058_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011323","article-title":"Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers","volume":"13","author":"KAUR","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105058_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","volume":"21","author":"LIU","year":"2024","journal-title":"Curr. Pharm. Anal."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:31:53Z","timestamp":1773880313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":115,"alternative-id":["S1040842825004469"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105058","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nectins: Orchestrating tumor progression and immune evasion","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105058"}}